SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from SEELOS THERAPEUTICS, INC. (SEEL) (CIK 0001017491) — Feb 3, 2020

SEELOS THERAPEUTICS, INC. (SEEL) (CIK 0001017491)
Date: Feb. 3, 2020 · CIK: 0001017491 · Accession: 0001136261-20-000032

AI Filing Summary & Sentiment

File numbers found in text: 333-236002

Date
February 3, 2020
Author
THE BENCHMARK COMPANY, LLC
Form
CORRESP
Company
SEELOS THERAPEUTICS, INC. (SEEL) (CIK 0001017491)

Letter

_

The Benchmark Company, LLC

150 East 58th Street, 17th Floor

New York, New York 10155

February 3, 2020

VIA FACSIMILE AND EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Washington, D.C. 20549

Re: SEELOS THERAPEUTICS, INC.

Registration Statement on Form S-1 (Registration No. 333-236002)

Concurrence in Acceleration Request

Ladies and Gentlemen:

The Benchmark Company, LLC ("Benchmark"), as representative of the underwriters for the referenced offering, hereby concurs in the request by Seelos Therapeutics, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:00 p.m. (Eastern Time), or as soon as practicable thereafter, on February 5, 2020, pursuant to Rule 461 under the Securities Act. Benchmark affirms that it is aware of its obligations under the Securities Act in connection with this offering.

Very truly yours,
THE BENCHMARK COMPANY, LLC

Show Raw Text
CORRESP
1
filename1.htm

_

The Benchmark Company, LLC

                   150 East 58th Street, 17th Floor

                   New York, New York 10155

February 3, 2020

VIA FACSIMILE AND EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Washington, D.C. 20549

Re: SEELOS THERAPEUTICS, INC.

        Registration Statement on Form S-1 (Registration No. 333-236002)

        Concurrence in Acceleration Request

Ladies and Gentlemen:

	The Benchmark Company, LLC ("Benchmark"), as representative of the underwriters for the referenced offering, hereby concurs in the request
by Seelos Therapeutics, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:00 p.m. (Eastern Time), or as soon as practicable thereafter, on February
5, 2020, pursuant to Rule 461 under the Securities Act.  Benchmark affirms that it is aware of its obligations under the Securities Act in connection with this offering.

 Very truly yours,

					THE BENCHMARK COMPANY, LLC

					By: /s/ Brad Carlsson

           Name: Brad Carlsson

          Title: Managing Director, Investment Banking